| Authors: |
Schmitt P; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Institute of Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Buch, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany., Hönig K; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Norcia MT; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Nogueira MF; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Flore V; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Precision Healthcare University Research Institute, Queen Mary University of London, London, UK., Vesperinas IS; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Villoro-Agud M; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Peng L; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Safyürek Z; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Tariq M; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Milojkovic A; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Translational Microbiome Research, Internal Medicine I and M3 Research Center, University Hospital Tuebingen, Tübingen, Germany., Anders K; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Pediatric Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Schröck E; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden, Germany.; ERN GENTURIS, Hereditary Cancer Syndrome Center Dresden, Dresden, Germany.; National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; German Cancer Consortium (DKTK), partner site: Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Sauer S; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany., Uyar B; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Akalin A; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Willimsky G; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Institute of Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Buch, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany., Haas S; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Precision Healthcare University Research Institute, Queen Mary University of London, London, UK.; Cluster of Excellence ImmunoPreCept, Charité - Universitätsmedizin Berlin, Berlin, Germany., Martínez-Reyes I; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. i.m.reyes@dkfz-heidelberg.de.; German Cancer Research Center (DKFZ), Heidelberg, Germany. i.m.reyes@dkfz-heidelberg.de.; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany. i.m.reyes@dkfz-heidelberg.de.; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany. i.m.reyes@dkfz-heidelberg.de.; Cluster of Excellence ImmunoPreCept, Charité - Universitätsmedizin Berlin, Berlin, Germany. i.m.reyes@dkfz-heidelberg.de., Blankenstein T; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. tblanke@mdc-berlin.de. |
